Oxurion has started to file for bankruptcy after the Phase IIb trial investigating its diabetic macular oedema (DMO) drug, THR-149, failed to meet its primary endpoint.

The Belgium-based company cited low cash reserves as the precipitating factor for filing for bankruptcy, as per the 20 November press release

THR-149 is a plasma kallikrein (PKal)-inhibitor for the treatment of DMO. DMO is a common complication of diabetes, which occurs due to the accumulation of excess fluid within the retina ultimately leading to blindness.

THR-149 Phase II data

THR-149 was evaluated in a randomised, multicentre, active-comparator Phase II trial (NCT04527107) against Bayer and Regeneron’s Eylea (aflibercept), which is the current standard of care.

The drug failed to meet its primary endpoint of improving the vision as much as the comparator at three months. The mean change for best corrected visual acuity (BCVA) from baseline at three months was -0.2 letters in the THR-149 treatment arm, compared to the +3.5 letters for the Eylea treatment arm.

THR-149 was the only drug in Oxurion’s pipeline. The company paused the clinical development of its second DMO candidate THR-687 in May 2022 after the drug failed to meet its endpoints in the Phase IIa trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In March, Oxurion signed a subscription funding agreement for convertible bonds with Atlas for up to €20.8m ($22.7m), with the funds invested over 24 months. The money was used to fund the Phase II trial. As of 16 November, Atlas had invested €11.5m of the total €20.8m.

DMO landscape

The DMO market is expected to grow to $11.1bn by 2031, driven by the increased prevalence of the disease, according to GlobalData.

GlobalData is the parent company of the Clinical Trials Arena.

Longer-acting anti-vascular endothelial growth factor (VEGF) therapies such as Roche’s Susvimo (ranibizumab), Kodiak Science’s KSI-301 (tarcocimab), and Bayer/Regeneron’s high-dose Eylea are expected to drive DMO market growth.

In July, Kodiak Sciences discontinued tarcocimab after the vascular endothelial growth factor (VEGF) inhibitor failed to meet the primary endpoint in two Phase III trials. However, the company resurrected the drug after announcing positive data from a Phase III diabetic retinopathy trial in November.

Other drugs currently in development for treating DMO include Allgenesis Biotherapeutics’ AG-73305. In November, the drug demonstrated a BCVA improvement of +6.4 letters in the Phase IIa clinical trial.

In February, Ocugen filed an investigational new drug (IND) application with the US Food and Drug Administration (FDA) to initiate a Phase I trial for its fusion protein OCU200.